Assess whether biosimilarity is analytically justified after a CRL citing

Situation

Labeling negotiator owns biosimilarity is analytically justified inside an RWE group proposing a post-marketing study instead of a new RCT with 505(b)(2) literature-to-product bridge table as the only packet. A CRL citing manufacturing, not efficacy is what changed the clock for this Pharma & Life Sciences Clinical and Evidence Strategy file.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• 505(b)(2) literature-to-product bridge table reads as Proceed under protocol once a CRL citing manufacturing, not efficacy is lined up to the same Pharma & Life Sciences population.
• 505(b)(2) literature-to-product bridge table is closer to Pause the pathway after a CRL citing manufacturing, not efficacy; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract.
• Escalate safety review is still live in 505(b)(2) literature-to-product bridge table for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT.
• 505(b)(2) literature-to-product bridge table is missing the fact labeling negotiator needs after a CRL citing manufacturing, not efficacy; stop this Pharma & Life Sciences close.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim labeling negotiator would keep.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against a CRL citing manufacturing, not efficacy and write the one fact that would move biosimilarity is analytically justified for labeling negotiator.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT.